Business Context and Reporting Period
This Form 8-K Current Report was filed by Collegium Pharmaceutical, Inc. on July 8, 2020, regarding events occurring on that date. The company is incorporated in Virginia and its common stock trades on the NASDAQ Global Select Market under the symbol "COLL".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The primary material change reported is the departure of a director:
- David Hirsch, M.D., Ph.D. notified the Board of his resignation as a Class I director and from all committees.
- The resignation became effective on July 9, 2020.
- The departure was to allow Dr. Hirsch to devote full-time efforts to other commitments.
- The Company confirmed the resignation was not the result of any disagreement regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. The document is limited to the notification of the director's departure.
Investor Verification Checklist
- Verify the effective date of Dr. Hirsch's resignation (July 9, 2020).
- Confirm the composition of the Board of Directors following this departure.
- Review the Company's most recent 10-Q or 10-K for current financial metrics, as this 8-K does not contain them.